Although researchers have used CD34 antibodies to label the tumor microvasculature by performing immunohistochemical (IHC) staining of lung cancer tumor tissues and to assess the relationship between MVD, tumor progression, and patient prognosis, the results of different studies have been controversial. This evidence concerns the gene CD34 and neoplasm.